Osborn Williams & Donohoe LLC Has $243,000 Holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Osborn Williams & Donohoe LLC boosted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 29.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,481 shares of the biopharmaceutical company’s stock after purchasing an additional 568 shares during the quarter. Osborn Williams & Donohoe LLC’s holdings in Alexion Pharmaceuticals were worth $243,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ALXN. UBS Group AG increased its position in shares of Alexion Pharmaceuticals by 7.3% in the 2nd quarter. UBS Group AG now owns 254,181 shares of the biopharmaceutical company’s stock valued at $33,293,000 after buying an additional 17,371 shares in the last quarter. CIBC Asset Management Inc increased its position in shares of Alexion Pharmaceuticals by 14.1% in the 2nd quarter. CIBC Asset Management Inc now owns 60,702 shares of the biopharmaceutical company’s stock valued at $7,951,000 after buying an additional 7,484 shares in the last quarter. Altman Advisors Inc. increased its position in shares of Alexion Pharmaceuticals by 13.6% in the 3rd quarter. Altman Advisors Inc. now owns 15,627 shares of the biopharmaceutical company’s stock valued at $1,531,000 after buying an additional 1,873 shares in the last quarter. Empire Life Investments Inc. increased its position in shares of Alexion Pharmaceuticals by 1.4% in the 2nd quarter. Empire Life Investments Inc. now owns 97,636 shares of the biopharmaceutical company’s stock valued at $12,788,000 after buying an additional 1,364 shares in the last quarter. Finally, Nomura Holdings Inc. increased its position in shares of Alexion Pharmaceuticals by 48.0% in the 2nd quarter. Nomura Holdings Inc. now owns 8,290 shares of the biopharmaceutical company’s stock valued at $1,083,000 after buying an additional 2,690 shares in the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ ALXN traded down $2.10 during mid-day trading on Friday, hitting $97.89. The company had a trading volume of 45,889 shares, compared to its average volume of 1,821,764. The company has a market capitalization of $23.50 billion, a PE ratio of 13.83, a price-to-earnings-growth ratio of 0.99 and a beta of 1.67. The firm has a 50-day simple moving average of $102.15 and a two-hundred day simple moving average of $119.03. The company has a current ratio of 4.04, a quick ratio of 3.56 and a debt-to-equity ratio of 0.26. Alexion Pharmaceuticals, Inc. has a one year low of $92.56 and a one year high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.51. The firm had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The business’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same period last year, the business posted $2.07 earnings per share. Sell-side analysts expect that Alexion Pharmaceuticals, Inc. will post 9.06 earnings per share for the current fiscal year.

A number of analysts recently commented on the stock. William Blair assumed coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, September 26th. They issued an “outperform” rating and a $146.00 price objective for the company. BidaskClub upgraded Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 11th. Stifel Nicolaus restated a “hold” rating on shares of Alexion Pharmaceuticals in a report on Friday, August 30th. Morgan Stanley decreased their price objective on Alexion Pharmaceuticals from $177.00 to $170.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Finally, TheStreet cut Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $159.76.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Read More: Trade War

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.